Integrating Experimentation and Quantitative Modeling to Enhance Discovery of Beta Amyloid Lowering Therapeutics for Alzheimer’s Disease

Drug discovery can benefit from a proactive-knowledge-attainment philosophy which strategically integrates experimentation and pharmacokinetic/pharmacodynamic (PK/PD) modeling. Our programs for Alzheimer’s disease (AD) illustrate such an approach. Compounds that inhibit the generation of brain beta...

Descripción completa

Detalles Bibliográficos
Autor principal: Lu, Yasong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2012
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463859/
https://www.ncbi.nlm.nih.gov/pubmed/23060797
http://dx.doi.org/10.3389/fphar.2012.00177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463859/
https://www.ncbi.nlm.nih.gov/pubmed/23060797
http://dx.doi.org/10.3389/fphar.2012.00177

Ejemplares similares